These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Diabetes and advanced glycoxidation end products. Huebschmann AG; Regensteiner JG; Vlassara H; Reusch JE Diabetes Care; 2006 Jun; 29(6):1420-32. PubMed ID: 16732039 [No Abstract] [Full Text] [Related]
26. [Therapeutic targets in diabetic vasculopathy]. Sánchez Ferrer CF An R Acad Nac Med (Madr); 2003; 120(4):659-69; discussion 669-74. PubMed ID: 15147053 [TBL] [Abstract][Full Text] [Related]
27. [Characteristics of atherosclerotic plaque in diabetics]. Breuer HW Herz; 2002 Mar; 27(2):189-92. PubMed ID: 12025464 [TBL] [Abstract][Full Text] [Related]
28. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Targher G; Bertolini L; Zoppini G; Zenari L; Falezza G Diabet Med; 2005 Aug; 22(8):999-1004. PubMed ID: 16026364 [TBL] [Abstract][Full Text] [Related]
31. [AGE-RAGE system in diabetic vascular complications]. Yamamoto Y; Yamamoto H Nihon Rinsho; 2010 Nov; 68 Suppl 9():39-44. PubMed ID: 21661142 [No Abstract] [Full Text] [Related]
32. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502 [TBL] [Abstract][Full Text] [Related]
33. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065 [TBL] [Abstract][Full Text] [Related]
34. Inflammation and neovascularization in diabetic atherosclerosis. Purushothaman KR; Meerarani P; Moreno PR Indian J Exp Biol; 2007 Jan; 45(1):93-102. PubMed ID: 17249333 [TBL] [Abstract][Full Text] [Related]
35. The role of endothelium in the pathogenesis of diabetic microangiopathy. La Selva M; Beltramo E; Passera P; Porta M; Molinatti GM Acta Diabetol; 1993; 30(4):190-200. PubMed ID: 8180411 [TBL] [Abstract][Full Text] [Related]
36. Nitric oxide and vascular responses in Type I diabetes. Chan NN; Vallance P; Colhoun HM Diabetologia; 2000 Feb; 43(2):137-47. PubMed ID: 10753034 [TBL] [Abstract][Full Text] [Related]
37. [AGE-RAGE system in the development of diabetic vascular complications]. Yamamoto Y Seikagaku; 2003 Sep; 75(9):1230-3. PubMed ID: 14577353 [No Abstract] [Full Text] [Related]
38. The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. Haller H; Drab M; Luft FC Clin Nephrol; 1996 Oct; 46(4):246-55. PubMed ID: 8905209 [TBL] [Abstract][Full Text] [Related]
39. A new dark side of the Maillard's products. Wautier JL Diabetes Metab; 2003 Feb; 29(1):86-7. PubMed ID: 12629454 [No Abstract] [Full Text] [Related]
40. [NEMOes, a new method to evaluate early atherosclerosis in rodent model]. Watada H; Kawamori R Nihon Rinsho; 2006 Nov; 64(11):2165-75. PubMed ID: 17087314 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]